Location: Obesity and Metabolism ResearchTitle: Modulating the microbiota as a therapeutic intervention for Type 2 Diabetes
|HUDA, NAZMUL - University Of California, Davis|
|KIM, MYUNGSUK - University Of California, Davis|
Submitted to: Frontiers in Endocrinology
Publication Type: Review Article
Publication Acceptance Date: 2/4/2021
Publication Date: 4/7/2021
Citation: Huda, N., Kim, M., Bennett, B.J. 2021. Modulating the microbiota as a therapeutic intervention for Type 2 Diabetes. Frontiers in Endocrinology. 12. Article 632335. https://doi.org/10.3389/fendo.2021.632335.
Technical Abstract: Mounting evidence suggested that the gut microbiota plays an important in metabolic disorders including Type 2 Diabetes Mellitus (T2DM) and associated underline diseases like obesity and low-grade inflammation. Microbial metabolites act as an intermediate phenotype that crosstalk between microbiota and host phenotype. Diet, host genetic architecture and immunity may shape gut microbiota, and gut microbiota influence health outcomes in return. Gut microbiota and its metabolites influence host biology of low-grade inflammation, insulin secretion and sensitivity, and plasma glucose levels. However, most of the reported studies are conducted in animals or observational in humans. Few approaches such as fecal microbiota transplantation (FMT), prebiotics and postbiotics supplementation studies have highlighted the causality. A holistic multi-omics approach with advanced compactional approaches will help us to better understand and harness the full potential benefit of the microbiota in the treatment of T2DM and designing precision preventive recommendations. In this review, we have critically summarized the current findings regarding the role of gut microbiota and its metabolites in T2DM. Then we discuss the potential underline mechanism and therapeutics strategies. Finally, we have commented on the future directions in this field.